UB Paderborn / Katalog / Suche / in CDI

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

JAMA neurology, 2020-02, Vol.77 (2), p.184

2020

Volltextzugriff (PDF)

Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis

European journal of neurology, 2017-05, Vol.24 (5), p.703-712

2017

Volltextzugriff (PDF)

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

Multiple sclerosis, 2010-02, Vol.16 (2), p.208-217

2010

Volltextzugriff (PDF)

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis

European journal of neurology, 2021-02, Vol.28 (2), p.579-586

2021

Volltextzugriff (PDF)

Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study

European journal of neurology, 2021-09, Vol.28 (9), p.3072-3079

2021

Volltextzugriff (PDF)

Improved survival of Swedish glioblastoma patients treated according to Stupp

Acta neurologica Scandinavica, 2018-10, Vol.138 (4), p.332-337

2018

Volltextzugriff (PDF)

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Acta neurologica Scandinavica, 2017-01, Vol.135 (1), p.17-24

2017

Volltextzugriff (PDF)

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab‐treated multiple sclerosis

European journal of neurology, 2017-01, Vol.24 (1), p.112-121

2017

Volltextzugriff (PDF)

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.86

2022

Volltextzugriff (PDF)

CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.847

2022

Volltextzugriff (PDF)

Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13

Journal of the neurological sciences, 2013-02, Vol.325 (1), p.79-85

2013

Volltextzugriff (PDF)

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

Multiple sclerosis, 2013-05, Vol.19 (6), p.765-774

2013

Volltextzugriff (PDF)

Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.677

2021

Volltextzugriff (PDF)

Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.21

2021

Volltextzugriff (PDF)

Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location

MULTIPLE SCLEROSIS JOURNAL, 2017, Vol.23, p.714

2017

Volltextzugriff (PDF)

IgA antibodies against tissue transglutaminase, endomysium and gliadin in idiopathic polyneuropathy

Acta neurologica Scandinavica, 2013-02, Vol.127 (2), p.109-115

2013

Volltextzugriff (PDF)

G.P.200

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.876-877

2014

Volltextzugriff (PDF)

Factors affecting the outcome of the first EEG in children with suspected epilepsy: a retrospective age-related comparison between awake and sleep recordings

Epilepsia (Copenhagen), 2023, Vol.64 (Supplement 2), p.446

2023

Volltextzugriff (PDF)

Cytokine mapping in cerebrospinal fluid and blood in multiple sclerosis patients without oligoclonal bands

Multiple sclerosis, 2012-05, Vol.18 (5), p.669-673

2012

Volltextzugriff (PDF)

Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings

Acta neurologica Scandinavica, 2010-07, Vol.122 (1), p.52-57

2010

Volltextzugriff (PDF)

Chronic symptoms are common in patients with neuroborreliosis - a questionnaire follow-up study

Acta neurologica Scandinavica, 2002-10, Vol.106 (4), p.205-208

2002

Volltextzugriff (PDF)

Transcriptional characteristics of CD4+ T cells in multiple sclerosis: Relative lack of suppressive populations in blood

Multiple sclerosis, 2011-01, Vol.17 (1), p.57-66

2011

Volltextzugriff (PDF)

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Annals of neurology, 2011-01, Vol.69 (1), p.83-89

2011

Volltextzugriff (PDF)

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Annals of neurology, 2020-05, Vol.87 (5), p.688-699

2020

Volltextzugriff (PDF)

Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis (vol 2023, 7587221, 2023)

Acta neurologica Scandinavica, 2023-10, Vol.2023

2023

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis

Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study

Improved survival of Swedish glioblastoma patients treated according to Stupp

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab‐treated multiple sclerosis

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study

Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients

Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab

Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location

IgA antibodies against tissue transglutaminase, endomysium and gliadin in idiopathic polyneuropathy

G.P.200

Factors affecting the outcome of the first EEG in children with suspected epilepsy: a retrospective age-related comparison between awake and sleep recordings

Cytokine mapping in cerebrospinal fluid and blood in multiple sclerosis patients without oligoclonal bands

Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings

Chronic symptoms are common in patients with neuroborreliosis - a questionnaire follow-up study

Transcriptional characteristics of CD4+ T cells in multiple sclerosis: Relative lack of suppressive populations in blood

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis (vol 2023, 7587221, 2023)

Suchergebnisse filtern